Myalepta (Metreleptin)

Metreleptin is a recombinant form of human leptin that binds to leptin receptors in the hypothalamus and peripheral tissues. This binding restores normal leptin signaling, which regulates appetite, energy expenditure, and glucose‑lipid metabolism, thereby helping to correct the metabolic disturbances seen in lipodystrophy.

The dosage of Myalepta is individualized. A qualified prescriber determines the appropriate amount based on the patient’s weight, severity of leptin deficiency, and clinical response. Dosing instructions are provided on the prescription label and should be followed exactly as directed by the healthcare professional.

Safety data for metreleptin in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians typically advise caution and close monitoring when considering treatment in these populations.

To request Myalepta, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling), and necessary import documentation.

Myalepta is a leptin replacement therapy, directly addressing the underlying hormone deficiency, whereas other options such as dietary management, insulin sensitizers, or lipid‑lowering agents treat downstream metabolic effects. By restoring leptin signaling, Myalepta can achieve broader metabolic improvements, but it is used specifically when leptin deficiency is confirmed.

Myalepta must be stored refrigerated between 2 °C and 8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If the temperature exceeds the recommended range, discard the medication and obtain a new supply.

Myalepta is given by subcutaneous injection, typically into the abdomen, thigh, or upper arm. The injection site should be rotated with each dose to minimize local irritation. Patients or caregivers should be trained by a healthcare professional on proper injection technique and aseptic handling.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, the development of anti‑leptin antibodies that may reduce efficacy, and rare cases of pancreatitis. Patients should be instructed to seek immediate medical attention if they experience symptoms like difficulty breathing, swelling, severe abdominal pain, or persistent nausea.

Myalepta is contraindicated in individuals with known hypersensitivity to metreleptin or any component of the formulation. It should also be avoided in patients receiving other leptin analogs or live vaccines without medical supervision, and in those where the risk of severe adverse reactions outweighs potential benefits.